- Home
- FTV vs BIIB Comparison
FTV vs BIIB Comparison
Compare FTV & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTV
- BIIB
- Stock Information
- Founded
- FTV 2015
- BIIB 1978
- Country
- FTV United States
- BIIB United States
- Employees
- FTV N/A
- BIIB N/A
- Industry
- FTV Industrial Machinery/Components
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- FTV Industrials
- BIIB Health Care
- Exchange
- FTV Nasdaq
- BIIB Nasdaq
- Market Cap
- FTV 26.7B
- BIIB 25.1B
- IPO Year
- FTV N/A
- BIIB 1991
- Fundamental
- Price
- FTV $73.71
- BIIB $146.79
- Analyst Decision
- FTV Buy
- BIIB Buy
- Analyst Count
- FTV 14
- BIIB 27
- Target Price
- FTV $86.73
- BIIB $252.20
- AVG Volume (30 Days)
- FTV 2.4M
- BIIB 1.5M
- Earning Date
- FTV 01-29-2025
- BIIB 02-11-2025
- Dividend Yield
- FTV 0.43%
- BIIB N/A
- EPS Growth
- FTV 7.50
- BIIB 10.05
- EPS
- FTV 2.50
- BIIB 11.06
- Revenue
- FTV $6,195,200,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- FTV $4.13
- BIIB N/A
- Revenue Next Year
- FTV $4.43
- BIIB N/A
- P/E Ratio
- FTV $29.46
- BIIB $13.27
- Revenue Growth
- FTV 3.06
- BIIB N/A
- 52 Week Low
- FTV $66.15
- BIIB $146.58
- 52 Week High
- FTV $87.10
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- FTV 31.65
- BIIB 23.28
- Support Level
- FTV $76.06
- BIIB $148.60
- Resistance Level
- FTV $77.34
- BIIB $154.24
- Average True Range (ATR)
- FTV 1.22
- BIIB 3.89
- MACD
- FTV -0.57
- BIIB -0.31
- Stochastic Oscillator
- FTV 1.30
- BIIB 1.15
About FTV Fortive Corporation
Fortive is a diversified industrial technology firm with a broad portfolio of mission-critical products and services that include field solutions, product realization, health, and sensing technologies. The company serves a wide range of end markets, including manufacturing, utilities, medical, and electronics. Fortive generated roughly $6.1 billion in revenue in 2023.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.